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sphere-forming stem-like oral cancer cells
Kaori Misuno1,2, Xiaojun Liu1,2, Sizhe Feng1,2 and Shen Hu1,2*Abstract
Introduction: The purpose of this study is to identify target proteins that may play important functional roles in
oral cancer stem-like cells (CSCs) using mass spectrometry-based quantitative proteomics.
Methods: Sphere-formation assays were performed on highly invasive UM1 and lowly invasive UM2 oral cancer cell
lines, which were derived from the same tongue squamous cell carcinoma, to enrich CSCs. Quantitative proteomic
analysis of CSC-like and non-CSC UM1 cells was carried out using tandem mass tagging and two-dimensional liquid
chromatography with Orbitrap mass spectrometry.
Results: CSC-like cancer cells were found to be present in the highly invasive UM1 cell line but absent in the lowly
invasive UM2 cell line. Stem cell markers SOX2, OCT4, SOX9 and CD44 were up-regulated, whereas HIF-1 alpha
and PGK-1 were down-regulated in CSC-like UM1 cells versus non-CSC UM1 cells. Quantitative proteomic analysis
indicated that many proteins in cell cycle, metabolism, G protein signal transduction, translational elongation,
development, and RNA splicing pathways were differentially expressed between the two cell phenotypes. Both
CREB-1-binding protein (CBP) and phosphorylated CREB-1 were found to be significantly over-expressed in CSC-like
UM1 cells.
Conclusions: CSC-like cells can be enriched from the highly invasive UM1 oral cancer cell line but not from the
lowly invasive UM2 oral cancer cell line. There are significant proteomic alterations between CSC-like and non-CSC
UM1 cells. In particular, CBP and phosphorylated CREB-1 were significantly up-regulated in CSC-like UM1 cells versus
non-CSC UM1 cells, suggesting that the CREB pathway is activated in the CSC-like cells.Introduction
Oral cancer, predominantly oral squamous cell carci-
noma (OSCC), is the sixth most common human cancer
worldwide. In the United States there were 39,400 new
cases of oral cavity and pharynx cancer and 7,900 related
deaths in 2011. Worldwide, however, there are more
than 480,000 new cases annually [1]. Patients diagnosed
with OSCC often present with symptoms at a late stage,
and there is a high recurrence rate after treatment, espe-
cially in those with neck lymph node metastasis [2]. Des-
pite clinical and treatment advances, the overall five-year
survival rates for oral cancer have remained low and
relatively unchanged during the past few decades [3,4].
The high mortality rate of oral cancer highlights the* Correspondence: shenhu@ucla.edu
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reproduction in any medium, provided the orimportance of studying the molecular and cellular mech-
anisms of this devastating disease.
Cancer stem cells (CSCs) comprise a small subpopula-
tion of cancer cells that possess the capacity to self-
renew and to cause the heterogeneous lineages of cancer
cells that comprise the tumor [5-7]. These cells appear
to be responsible for tumor initiation and sustained
growth, and their presence is believed to play an import-
ant role in tumor metastasis and resistance to chemo-
therapy or radiation therapy [8]. In this regard, studying
CSC biology is critical for the discovery of novel thera-
peutic targets in human cancers. Enrichment and isola-
tion of CSC-like cells have been made possible by using
various methods including efflux of vital dyes by multi-
drug transporters (for example, ABC transporters),
increased enzymatic activity (for example, aldehyde de-
hydrogenase, ALDH), sphere-forming assays, and cell
surface expression of specific stem cell markers [9-14].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mary head and neck squamous cell carcinomas (HNSCC)
that expressed basal cell markers, cytokeratin 5 and 14,
and the stem cell marker BMI1. They found that as few as
5,000 CD44+ HNSCC cells gave rise to a new tumor when
transplanted into the flank of immunocompromised mice,
whereas CD44- cells failed to form tumors in the mice
[15,16]. Clay et al. demonstrated that as few as 500
ALDHhigh cancer cells could form new HNSCC tumors in
immunocompromised mice, ten-fold fewer cells than the
CD44+ subpopulation. Most of the ALDHhigh cells were
also CD44+. However, a small fraction of ALDH+ cells
remained CD44− [12]. Oral CSC-like cells can also be iso-
lated from OSCC using a sphere-formation assay by culti-
vating the cancer cells in serum-free medium with growth
factors such as basic fibroblast growth factor (bFGF) and
epidermal growth factor (EGF). Using this approach,
Chiou et al. isolated oral CSC-like cells that expressed
high levels of stem/progenitor cell markers, OCT-4,
Nanog, CD117, Nestin, CD133, as well as ABC trans-
porter ABCG2. The CSC-like cells also displayed in-
duced differentiation abilities and enhanced migration
and invasion potential. Positive correlations of OCT-4,
Nanog, or CD133 expression with tumor stage were
observed in OSCC patients, and Nanog/OCT-4/CD133
triple-positive patients had the worst survival prognosis
[17]. Similarly, Zhang et al. identified a subpopulation of
CD133+ CSC-like cells that possess higher clonogenicity,
invasiveness and increased in vivo tumorigenicity when
compared to CD133- counterparts. Meanwhile, CD133+
CSCs were substantially resistant to standard chemother-
apy, in which both in vitro and in vivo treatment with pac-
litaxel resulted in a marked enrichment for CD133+ CSCs.
These findings suggest that CD133+ cells represent a small
subpopulation of CSCs that may contribute to chemore-
sistance in oral cancer [13].
cAMP responsive element binding protein 1 (CREB-1)
is a transcription factor that binds to the cAMP response
element, a DNA nucleotide sequence present in many
viral and cellular promoters. The protein belongs to the
leucine zipper family of DNA-binding proteins. Various
serine/threonine kinases, such as ribosomal protein S6
kinase, protein kinase C, protein kinase B/AKT, and
mitogen- and stress-activated protein kinase (MSK-1),
may activate CREB-1 in cells via phosphorylation [18].
Activated CREB-1 then recruits transcription co-acti-
vators CREB-1-binding protein (CBP)/p300 and relocates
to the nucleus to activate a number of downstream
targets, especially those genes involved in cell growth,
survival and cell-cycle regulation. CREB-1 has been
implicated in multiple human cancers as well as di-
verse cellular processes. The protein regulates a number
of genes that play important roles in promoting oncoge-
nesis, such as c-fos, cyclins A1 and cyclin D1 [19,20].Quantitative proteomics using tandem mass spectro-
metry (MS) with stable isotope labeling is an important
technology for measuring protein levels in a global fash-
ion ([21]. Disease and control samples can be labeled
with ‘heavy’ or ‘light’ isotopes and then measured by MS.
The intensity ratios of the peptide peaks (or reporter ion
peaks) in a given mass spectrum represent relative abun-
dance of the proteins. TMT (tandem mass tag) and
iTRAQ iIsobaric tag for relation and absolute quantita-
tion) are isobaric chemical tags that enable concurrent
identification and quantitation of proteins in different
samples using tandem MS. The isobaric tags can be
cleaved during collision-induced dissociation (CID) to
yield an isotope series (reporter ions) representing the
quantity of a single peptide of known mass from mul-
tiple samples. Since the peptide remains attached to the
isobaric tags until CID is conducted, the peptide is simul-
taneously fragmented for sequence identification [22,23].
In this study, we have enriched and isolated oral
CSC-like cells from a highly invasive UM1 oral cancer
cell line and characterized the expression of stem cell
markers in these cells. By using TMT labeling and li-
quid chromatography with tandem mass spectrometry
(LC-MS/MS), we have performed a comparative pro-
teomic analysis of CSC-like and non-CSC UM1 cells.
Transcription co-activator CBP was found to be over-
expressed whereas CREB-1 was significantly phosphory-
lated in CSC-like cells. Our findings suggest that the
CREB-1 pathway is activated in the CSC-like UM1 cells
and may play an important role in maintaining the stem-
ness of oral CSC-like cells.
Methods
Cell culture
UM1 and UM2 cell lines were cultured in (D)MEM with
10% fetal bovine serum and 1% penicillin/streptomycin
(Invitrogen, Carlsbad, CA, USA) and maintained at 37°C
in a humidified atmosphere of 5% CO2. When the can-
cer cells reached confluence of approximately 90%, the
culture medium was changed to serum-free medium
((D)MEM) containing 1% penicillin/streptomycin and
growth factors bFGF (10 ng/ml) and EGF (10 ng/ml)
(Geminni Bio, Sacramento, CA, USA). The spherogenic
and non-spherogenic UM1 cancer cells were harvested
using trypsinization.
Western blotting
Following separation on a NuPAGENovex 4% to 12%
Bis-Tris gel (Invitrogen) at 100 V, the proteins were trans-
ferred to a nitrocellulose membrane (Bio-Rad, Hercules,
CA, USA). Afterwards, the membranes were blocked for
one hour in 5% milk and then incubated with the following
primary antibodies: rabbit polyclonal antibodies anti-CD44,
anti-transketolase, anti-SOX-9, anti-CREB-1 and anti-
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Cruz, CA, USA), rabbit polyclonal antibodies anti-SOX-2 and
anti-hypoxia inducible factor 1 α (Gene Tex, Irvine, CA,
USA), goat polyclonal antibody anti-OCT-3/4 and mouse
monoclonal antibody anti-phosphoglycerate kinase 1 (Santa
Cruz Biotechnologies). Blots were then washed with TBST
(Tris-Buffered Saline with Tween 20) (1x), incubated with
secondary antibody (Amersham, Piscataway, NJ, USA), and
finally developed with the ECL plus detection kit (GE
healthcare, Pittsburg, PA, USA).Tandem mass tagging
Quantitative proteomic analysis was performed using TMT
labeling (TMT-6plex, Thermo Fisher, Waltham, MA, USA)
and two-dimensional LC-MS/MS. CSC-like and non-CSC
cells were lysed on ice with a POLYTRON homogenizer
(Kenematika, Bohemia, NY, USA) in 8 M urea containing
protease inhibitor cocktail (Calbiochem, San Diego, CA,
USA). Equal amounts of proteins (100 μg) from either CSC-
like or non-CSC UM1 cells were reduced with dithiothreitol,
alkylated with iodoacetamide and digested with trypsin
overnight. The resulting peptides were then labeled with
TMT-126 (CSC-like) and TMT-127 (non-CSC) according
to the manufacturer’s protocol. Afterwards, we combined
the labeled samples and fractionated the combined sample
with a strong-cation exchange spin column (VIVAPURE S
mini H, Sartorius Stedim, Bohemia, NY, USA). The initial fil-
trate and eight elutions under different concentrations of so-
dium acetate (2.5 mM, 5 mM, 10 mM, 20 mM, 50 mM,
100 mM, 250 mM and 1 M) were collected, vacuum-dried
and re-suspended in 0.1% formic acid for LC-MS/MS analysis.Liquid chromatography with tandem mass spectroscopy
Fractionated peptide samples were loaded on an Agilent
nano-trap column (Santa Clara, CA, USA) and washed for
10 minutes at 6 uL/minute. Chromatography was performed
using Eksigent two-dimensional-LC nanoflow system opera-
ting at 400 nL/minute and a 90-minute gradient. Separation
was performed on a Microm 100 × 0.1 mm C18AQ column
(200A◦, 3 μm) using solvent A (0.1% formic acid) and solvent
B (99.9% ACN, 0.1% formic acid) over a 90-minute gradient:
0% to 30% B (60 minutes), 35% to 80% B (10 minutes), 80%
B (5 minutes), and then the column was re-equilibrated.
Data-dependent LC-MS-MS was performed using an
Orbitrap LTQ XL mass spectrometer (Thermo Fisher, San
Jose, CA, USA) with the MS scan performed in the Orbitrap
analyzer using two microscans of maximum time 50 ms and
an automatic gain control of 1E5. The top five ions of inten-
sity greater than 5,000 (excluding single charge states) were
selected for MS/MS. In each cycle, a MS-MS fragmentation
was generated using subsequent CID (collision energy 35)
and HCD (Higher energy collision dissociation) (collision
energy 42) scans performed in the LTQ Iontrap andOrbitrap cell, respectively, which were then combined in
data processing to obtain quantitative and qualitative data.Data analysis
Database searching was performed using the Proteome Dis-
coverer 1.2 (Thermo Fisher Scientific) against the Inter-
national Proteome Index (IPI) database (IPI.HUMAN.
v3.16, 62322 entries). A workflow was created for the pur-
pose of analysis of LC-MS/MS raw data. First, the raw data
files were loaded into the Spectrum Files. The parameters in
the Spectrum Selector were set up as default, and TMT
6-plex (TMT-126 and TMT-127) was chosen in Re-
porter Ion Quantifier. SEQUEST algorithm was used
for data searching to identify proteins. The parameters for
SEQUEST database searching were as follows: missed
cleavage of two; the dynamic modifications were oxidation
(+15.995 Da) (M), deamidation (+0.984 Da) (N) and phos-
phorylation (+79.9966 Da) (S, T, Y). The static modifica-
tions were TMT-6plex (+229.163 Da) (any N-terminus and
K) and Carbamidomethyl (+57 Da) (C). The false discovery
rate was below 1% for protein identification. For protein
quantitation, ‘Normalize on Protein Median’ was used for
normalization and proteins with a fold change of 1.2 were
generally considered as differentially expressed. The gene
ontology (GO) and pathway analyses were performed using
the DAVID bioinformatics resource [24].Results
Enrichment and isolation of CSC-like cells
To enrich and isolate CSC-like cells, both UM1 and
UM2 cancer cells were maintained in serum-free media
containing growth factors bFGF and EGF. After three
weeks, a subset of UM1 cells started to form sphero-
genic aggregates, as shown in Figure 1. Significant for-
mation of spheres was observed in the UM1 cells during
the fourth week. So far, we have obtained spherogenic
CSC-like cells from all 18 plates (10 cm) of UM1 cells
cultured under serum-free medium (100% successful
rate). In contrast, UM2 cells were not spherogenic at all
in serum-free medium and lysed rapidly after three
weeks. To isolate the spherogenic UM1 cells, the cul-
tures were carefully treated with trypsin in the fifth
week. The sphere-like cellular aggregates became de-
tached from the adherent layer of cancer cells and were
harvested. Afterwards, the adherent cells were collected
with continuous trypsinization. The cells present in the
sphere-like aggregates are considered as CSC-like cancer
cells whereas the bottom layer of adherent cells are con-
sidered as non-CSC cancer cells. Both types of cells were
then lysed in 8 M urea with a homogenizer for subse-
quent analysis of stem cell markers and quantitative pro-
teomics. CSC-like UM1 cells were spherogenic cellular
aggregates from all the twenty-one culture dishes.
Figure 1 A subset of UM1 oral cancer cells were spherogenic when cultured in serum-free medium containing growth factors bFGF
and EGF for three to four weeks (A). A close-up of the spherogenic cancer cells is shown in (B). bFGF, basic fibroblast growth factor; EGF,
epidermal growth factor.
Figure 2 Western blot analysis of CD44, octamer-binding
transcription factor 4 (OCT4), sex determining region Y-box 2
(SOX2), SOX9, transketolase (TKT), hypoxia-inducible factor 1
alpha (HIF-α) and phosphoglycerate kinase 1 (PGK-1) in CSC-like
and non-CSC UM1 cells (A). The normalized levels of all seven
proteins are shown in (B). Stem cell markers CD44, OCT4, SOX2 and
SOX9 were up-regulated in CSC-like UM1 cells whereas HIF-α and
PGK-1 were down-regulated in CSC-like cells when compared to
non-CSC UM1 cells (n = 3). No significant difference in expression
was observed for TKT. *, P <0.05; **, P <0.01. CSC, cancer stem cells.
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To characterize the CSC-like cells (cells present in the
sphere-like aggregates), we compared the expression
levels of CD44, OCT-4, SOX2 and SOX9 between CSC-
like (spherogenic) and non-CSC (non-spherogenic) UM1
cancer cells with Western blotting. All the stem cell
markers were significantly up-regulated in CSC-like
UM1 cells when compared to non-CSC UM1 cells
(Figure 2).
Expression of HIF-1α and PGK-1 in CSC-like cells
We also compared the expression levels of hypoxia-
inducible factor HIF-1α and two metabolic enzymes,
transketolase (TKT) and phosphoglycerate kinase 1
(PGK-1), between CSC-like and non-CSC UM1 cells
(Figure 2) with Western blotting. TKT was not signifi-
cantly different between the two cell phenotypes. How-
ever, both HIF-1α and PGK1 were down-regulated in
CSC-like cells versus non-CSC cells.
Quantitative proteomic analysis of CSC-like UM1
cancer cells
Using TMT labeling and two-dimensional LC-MS/MS,
we performed a comparative proteomic analysis of CSC-
like and non-CSC UM1 cells. The database search with
the Proteome Discoverer indicated that 4,397 proteins
had at least one tryptic peptide matched with high confi-
dence and 936 peptides (21%) were labeled with TMT
(Additional file 1: Table S1). There were 1,026 proteins
with two tryptic peptides matched with high confidence,
including 425 with two TMT-labeled peptides (Figure 3).
Many proteins on cell cycle, metabolism, small G pro-
tein signal transduction, translational elongation, deve-
lopment, and RNA splicing pathways were found to be
differentially expressed (>1.2 fold) between the CSC-like
and non-CSC UM1 cells (Figure 4, Tables 1, 2, 3 and 4).
CREB pathway is activated in CSC-like UM1 cancer cells
Quantitative proteomic analysis revealed that CBP was
over-expressed in CSC-like cells when compared to non-CSC UM1 cells. This was confirmed by Western blot
analysis, as shown in Figure 5. Intriguingly, although no
significant difference in the total expression level of
CREB-1 was observed between non-CSC and CSC-like
cells, the expression level of phosphorylated CREB-1
Figure 3 Quantitative proteomic analysis of CSC-like and non-CSC UM1 cancer cells using tandem mass tagging (TMT) and
two-dimensional LC-MS/MS. Ratios of 127 to 126 represent the relative levels of proteins between non-CSC (TMT-127) and CSC-like (TMT-126)
UM1 cells. (A) depicts the corresponding number of protein IDs with ≥1 matched peptide (n = 4,397), ≥2 matched peptides (n = 1,026), ≥1
matched and TMT-labeled peptide (n = 936), or ≥2 matched and TMT-labeled peptides (n = 425). (B) illustrates the TMT-127/TMT-126 ratios for
936 proteins with ≥1 matched and TMT-labeled peptide. (C) illustrates the TMT-127/TMT-126 ratios for 425 proteins with ≥2 matched and
TMT-labeled peptides. CSC, cancer stem cells; LC-MS/MS, liquid chromatography-tandem mass spectroscopy.
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cells than in non-CSC UM1 cells.
Discussion
To enrich CSCs from oral cancer cell lines, we main-
tained UM1 and UM2 oral cancer cells in serum-free
culture medium with bFGF and EGF. Both UM1 and
UM2 cell lines were initially established from the same
tongue cancer patient [25]. UM1 cells appeared to be
highly invasive whereas UM2 cells were found to be
lowly invasive. Our trans-well invasion assays indeed
demonstrated that UM1 cancer cells were at least eight-
fold more invasive than UM2 cancer cells (data not
shown). After being maintained in serum-free medium for
three weeks, a subset of UM1 cells started to form sphere-
like cellular aggregates (CSC-like). It is well known that
serum-free medium with selected growth factors is cap-
able of maintaining cancer cells in the undifferentiated
state. In fact, CSC-like cells enriched with serum-free
medium containing bFGF and EGF mirror the phenotype
and genotype of primary tumors more closely than do
cancer cell lines cultured in complete serum medium [26].
Our experiment agreed with these previous studies and
further confirmed that oral CSC-like cells can be enriched
with sphere-formation assay under serum-free culture
conditions [13,17]. In contrast, the UM2 tongue cancer
cells were not spherogenic and eventually lysed after three
weeks of culture in serum-free medium. UM1 and UM2cell lines were derived from the same patient’s tongue
squamous cell carcinoma. Our studies suggest that a CSC-
like subpopulation is only present in highly invasive
UM1 cancer cells but absent in the lowly invasive UM2
cancer cells.
To confirm that the spherogenic UM1 cells are CSC-
like, we compared the expression levels of stem cell
markers, including CD44, OCT4, SOX2 and SOX9, be-
tween the isolated spherogenic and non-spherogenic
UM1 cells. All these markers were found to be signifi-
cantly up-regulated in spherogenic cells (Figure 2). CD44
is a CSC marker known to be involved in cancer cell adhe-
sion and migration. The expression of CD44 has been cor-
related with tumor progression and poor diagnosis in
oral/head and neck cancer. Prince et al. purified CSC-like
cells from HNSCC by selecting the CD44+ cells [15,16].
The CD44+ cells were found to be tumorigenic and differ-
entially expressed the stem cell marker gene BMI1, at both
the RNA and protein levels. In the study by Chiou et al.,
CD44 was found to be down-regulated whereas CD133
was over-expressed in their enriched CSC-like cells. As
the authors pointed out, this may be due to the fact that
the serum-free cultivation mainly enriched the CD133+
CSCs [17].
OCT4 and SOX2 are frequently used as markers for
undifferentiated cells. OCT-4 is critically involved in the
self-renewal of undifferentiated embryonic stem cells as
evidenced by the fact that gene knockdown of OCT4
Figure 4 Gene ontology analysis of the quantified proteins according to the biological process (A), cellular component (B) and
molecular function (C).
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[27]. Previous studies also indicated that higher OCT4
expression correlates with oral cancer progression and
metastasis, as well as contributes to oral cancer patient
mortality. It is speculated that deregulation of Oct-4
gene may perturb the normal differentiation program
and predispose to tumor formation [28]. SOX2 is a
member of the Sox family of transcription factors, which
serves as a key regulator of stem cell pluripotency and
differentiation. The LIF (leukemia inhibitory factor) sig-
naling pathway, which maintains pluripotency in mouse
embryonic stem cells, activates SOX2 downstream of the
JAK-STAT signaling pathway and Nanog downstream of
PI3K-AKT, respectively, and maintains the expression of
OCT4 [29]. As a feedback mechanism, both OCT4 and
SOX2 positively regulate the transcription of pluripo-
tency circuitry proteins in the LIF signaling pathway. In
fact, SOX2 is up-regulated in lung squamous cell carci-
noma, and activates cellular migration and anchorage-
independent growth [30]. Similar to SOX2, SOX9 plays
a pivotal role in many stages of mammalian develop-
ment, with its levels strictly controlled for normal em-
bryogenesis. The expression of SOX9 is up-regulated ina variety of human cancers, which correlates with tumor
malignancy and progression. In particular, SOX9 pro-
motes proliferation and prevents differentiation in intes-
tinal stem cell/progenitors, acting downstream of Wnt
signaling [31]. Overall, the significant over-expression of
stem cell markers SOX2, OCT4, SOX9 and CD44 sug-
gests that the cells present in spherical aggregates are
CSC-like whereas the non-spherogenic, adherent layer
of cells are non-CSC cancer cells.
We also compared the expression of HIF-1α and two
metabolic enzymes PGK1 and TKT between CSC-like
and non-CSC cells. TKT, a critical metabolic enzyme of
the pentose phosphate pathway, was not significantly dif-
ferent between the two cell types. However, both HIF-1α
and PGK1 were found to be down-regulated in CSC-like
cancer cells compared to non-CSC cancer cells. HIF-1 is a
heterodimeric transcription factor that consists of two sub-
units, the HIF-1β subunit which is constitutively expressed
and the HIF-1α subunit which is regulated by oxygen levels.
The protein plays an important role in cancer cell metabol-
ism by activating the genes for glucose transporters and
glycolytic enzymes resulting in an increased glycolytic rate
[32]. PGK1 is an ATP-generating enzyme in the glycolytic
Table 1 A list of differentially expressed proteins regulating transcription or translation
Accession # Peptides MW [kDa] Calc. pI 127/126 non-CSC:CSC SD127/126 Protein description
IPI:IPI00410017.1 2 61.1 9.07 2.592 1.429 Poly(A)-binding protein 1
IPI:IPI00375141.1 5 412.1 5.83 1.456 0.421 Dystrophin
IPI:IPI00009771.5 2 69.9 5.59 1.440 0.451 Lamin-B2
IPI:IPI00291783.3 3 168.5 6.60 1.337 0.164 Gem-associated protein 5
IPI:IPI00183085.2 2 35.2 6.34 1.282 0.112 Highly similar to N-myc downstream regulated 1
IPI:IPI00179700.3 3 11.7 10.32 1.227 0.179 High mobility group protein HMG-I/HMG-Y
IPI:IPI00651769.1 2 126.6 5.63 0.832 0.140 Myelin transcription factor 1-like protein
IPI:IPI00465070.6 8 15.3 11.12 0.812 0.169 Histone H3.1
IPI:IPI00141938.3 5 12.1 10.46 0.801 0.070 H2A histone family, member V isoform 2
IPI:IPI00328737.1 2 98.6 8.40 0.794 0.110 Zinc finger protein 598
IPI:IPI00006196.2 3 236.4 5.80 0.792 0.073 Nuclear mitotic apparatus protein 1, asymmetric
division related
IPI:IPI00027252.6 4 33.3 9.83 0.789 0.109 Prohibitin-2, mediator of transcriptional repression
IPI:IPI00745230.1 2 343.9 8.47 0.788 0.008 REV3-like, catalytic subunit of DNA polymerase zeta
IPI:IPI00000897.1 2 218.8 7.37 0.779 0.148 Probable helicase with zinc-finger domain
IPI:IPI00220834.7 3 82.5 5.81 0.773 0.195 ATP-dependent DNA helicase 2 subunit 2
IPI:IPI00386211.3 3 330.3 5.08 0.760 0.301 1
IPI:IPI00027107.5 5 49.8 7.61 0.760 0.136 Tu translation elongation factor, mitochondrial
IPI:IPI00021405.3 26 74.1 7.02 0.755 0.170 Isoform A of Lamin-A/C
IPI:IPI00020153.2 2 416.1 7.55 0.749 0.122 Zinc finger protein 231
IPI:IPI00219038.8 7 15.2 11.27 0.718 0.161 Histone H3.3
IPI:IPI00166612.9 2 448.9 4.78 0.711 0.063 Cardiomyopathy associated 5 protein
IPI:IPI00337766.5 3 91.7 7.39 0.705 0.215 Zinc finger, CCHC domain containing 2
IPI:IPI00642900.2 3 241.1 7.05 0.697 0.147 Transcription repressor CCR4-NOT transcription
complex subunit 1
IPI:IPI00401829.3 2 93.6 6.71 0.645 0.231 Coiled-coil domain-containing protein 175
IPI:IPI00216457.6 6 14.0 10.90 0.628 0.093 Histone H2A type 2-A
IPI:IPI00065310.2 3 75.3 5.68 0.626 0.266 Coiled-coil domain-containing protein 27
IPI:IPI00014213.1 2 101.9 8.22 0.617 0.295 Probable leucyl-tRNA synthetase, mitochondrial precursor
IPI:IPI00294575.7 2 91.8 7.02 0.577 0.628 Cell division cycle protein 27 homolog
IPI:IPI00020991.2 2 61.1 9.01 0.568 0.122 CDKN2A interacting protein
IPI:IPI00171611.5 8 15.4 11.27 0.563 0.177 H3 histone family, member M
IPI:IPI00007928.4 2 273.4 8.84 0.550 0.196 Pre-mRNA-processing-splicing factor 8
IPI:IPI00021520.1 2 37.2 9.11 0.478 0.100 Glucocorticoid receptor AF-1 coactivator-1
IPI:IPI00619932.4 2 265.2 8.53 0.382 0.047 CREB-binding protein
IPI:IPI00024163.1 2 155.6 8.48 0.303 0.367 DNA-directed RNA polymerase III largest subunit
IPI:IPI00387050.3 2 55.5 9.57 0.216 0.349 BUD13 homolog, splicing factor
IPI:IPI00015557.3 2 17.7 6.01 0.097 0.248 Coiled-coil domain-containing protein 48
CSC, cancer stem cells; MW, molecular weight.
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prostate cancer cell-derived PGK-1 induces osteoblastic dif-
ferentiation of bone marrow stromal cells, affecting bone
formation at the metastatic site. PGK-1 may also induce the
differentiation of gastric cancer stem cells [33,34]. Since
HIF-1α positively regulates glycolytic enzymes, includingPGK1, it is not surprising that PGK-1 was down-regulated,
the same as HIF-1α, in CSC-like UM1 cells.
Functional analysis of the differentially expressed pro-
teins using DAVID revealed multiple pathways signifi-
cantly associated with CSCs, such as ribosome, cell
cycle, development, glycolysis, translation elongation,
Table 2 A list of quantified enzymes including metabolic enzymes between CSC-like and non-CSC UM1 cells
Accession # Peptides MW [kDa] Calc. pI 127/126 non-CSC:CSC SD127/126 Protein description
IPI:IPI00219568.3 5 44.6 8.54 1.389 0.190 Phosphoglycerate kinase, testis specific (PGK2)
IPI:IPI00289800.7 2 59.2 6.84 1.339 0.014 Glucose-6-phosphate dehydrogenase
IPI:IPI00005705.1 2 37.0 6.54 1.258 0.161 Serine/threonine-protein phosphatase 1, catalytic
subunit, gamma isozyme
IPI:IPI00218353.3 3 121.0 7.75 1.210 0.287 Probable cation-transporting ATPase 13A1
IPI:IPI00007188.4 7 32.7 9.74 0.866 0.085 ADP/ATP translocase 2
IPI:IPI00027442.3 2 106.7 5.49 0.861 0.226 Alanyl-tRNA synthetase
IPI:IPI00440493.2 9 59.7 9.13 0.824 0.161 ATP synthase alpha chain, mitochondrial precursor
IPI:IPI00029144.1 2 130.2 5.21 0.818 0.055 Serine/threonine-protein phosphatase 2A 72/130 kDa
regulatory subunit B
IPI:IPI00014375.1 2 109.2 5.50 0.790 0.164 Glutamyl aminopeptidase
IPI:IPI00513928.1 2 33.0 8.15 0.768 0.076 Acyl-coenzyme A thioesterase 2
IPI:IPI00018206.3 3 47.4 9.01 0.734 0.141 Aspartate aminotransferase, mitochondrial precursor
IPI:IPI00291006.1 8 35.5 8.68 0.732 0.194 Malate dehydrogenase, mitochondrial precursor
IPI:IPI00297084.7 2 50.8 6.55 0.731 0.011 Dolichyl-diphosphooligosaccharide-protein
glycosyltransferase
IPI:IPI00303476.1 15 56.5 5.40 0.730 0.203 ATP synthase beta chain, mitochondrial precursor
IPI:IPI00022774.2 4 89.1 5.26 0.665 0.078 Transitional endoplasmic reticulum ATPase
IPI:IPI00438875.2 2 98.0 7.34 0.658 0.281 Channel kinase 2 (Isoform M6-kinase 2 of Transient
receptor potential cation channel subfamily M
member 6)
IPI:IPI00640240.1 2 58.6 9.13 0.648 0.149 Serine palmitoyltransferase, long chain base
subunit 2-like
IPI:IPI00646947.1 3 95.1 5.77 0.626 0.222 Highly similar to Sarcoplasmic/endoplasmic
reticulum calcium ATPase 1
IPI:IPI00009634.1 4 49.9 9.11 0.546 0.198 Sulfide:quinone oxidoreductase, mitochondrial
precursor
IPI:IPI00657779.1 2 16.5 9.58 0.492 0.172 Peptidylprolyl isomerase F
IPI:IPI00552972.2 3 56.3 6.33 0.473 0.208 Dolichyl-diphosphooligosaccharide-protein
glycosyltransferase subunit 2
IPI:IPI00658151.1 3 354.1 8.51 0.465 0.276 Striated muscle preferentially expressed protein kinase
IPI:IPI00022314.1 5 24.7 8.25 0.400 0.263 Superoxide dismutase [Mn], mitochondrial precursor
IPI:IPI00007611.1 3 23.3 9.96 0.353 0.267 ATP synthase,subunit O, mitochondrial precursor
CSC, cancer stem cells; MW, molecular weight.
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RNA splicing. GO analysis of the quantified proteins
showed similar functional categories as the pathway
analysis (Figure 4). A number of the differentially
expressed proteins are transcription factors/activators/
suppressors, translation elongation factors, or spicing
factors (Table 1). For instance, both prohibitin-2 (PHB2)
and lamin A were found to be up-regulated whereas
Lamin-B2 was down-regulated in CSC-like UM1 cells.
PHB2 acts as a mediator of transcriptional repression by
nuclear hormone receptors via recruitment of histone
deacetylases. Recent studies have demonstrated that
epidermal stem cells are highly dependent on PHB2
for maintaining mitochondrial function [35]. Nuclearlamins are fibrous proteins which interact with
membrane-associated proteins to form the nuclear lamina
on the interior of the nuclear envelope. They are involved
in transcriptional regulation, breakdown and reformation
of the nuclear envelope during mitosis, as well as the
positioning of nuclear pores. In fact, colorectal cancer
patients expressing lamin A/C in their tumor tissue
were found to have a higher risk of mortality com-
pared to patients with lamin A/C-negative tumors.
The poor outcome associated with lamin A/C-positive tu-
mors might be reflective of a more stem-cell-like pheno-
type [36,37].
The proteomic analysis suggests that metabolic path-
ways may be different between the CSC-like and non-CSC
Table 3 A list of quantified proteins related to G protein signal transduction
Accession # Peptides MW [kDa] Calc. pI 127/126 non-CSC:CSC SD127/126 Protein description
IPI:IPI00009342.1 9 189.1 6.48 0.938 0.206 Ras GTPase-activating-like protein IQGAP1
IPI:IPI00183572.3 3 174.0 7.02 0.884 0.415 Dedicator of cytokinesis protein 7, guanine
nucleotide exchange factor
IPI:IPI00383449.2 3 23.5 9.95 0.884 0.115 Ras-related protein Rab-15
IPI:IPI00337802.3 3 100.9 7.71 0.867 0.273 Disheveled-associated activator of morphogenesis 1
IPI:IPI00015148.3 2 20.8 5.78 0.852 0.051 Ras-related protein Rap-1b
IPI:IPI00016342.1 4 23.5 6.70 0.848 0.143 Ras-related protein Rab-7
IPI:IPI00746773.1 2 179.4 7.66 0.804 0.100 IQ motif containing GTPase activating protein 3
IPI:IPI00216989.5 3 82.4 7.69 0.740 0.125 G protein-regulated inducer of neurite outgrowth 3
IPI:IPI00008964.3 4 22.2 5.73 0.733 0.164 Ras-related protein Rab-1B
IPI:IPI00016513.5 3 22.5 8.38 0.727 0.120 Ras-related protein Rab-10
IPI:IPI00607850.1 2 176.9 6.58 0.654 0.072 Citron Rho-interacting kinase
IPI:IPI00168769.6 3 222.4 7.81 0.647 0.244 Exophilin 5 (Rab GTPase binding protein)
IPI:IPI00455852.1 4 91.9 8.25 0.642 0.234 Rho guanine nucleotide exchange factor 15
IPI:IPI00022479.4 3 531.9 6.04 0.554 0.264 Guanine nucleotide exchange factor p532
CSC, cancer stem cells; MW, molecular weight.
Table 4 A list of differentially expressed proteins related to development or differentiation
Accession # Peptides MW [kDa] Calc. pI 127/126 non-CSC:CSC SD127/126 Protein description
IPI:IPI00031547.1 3 107.4 5.00 0.146 0.158 Desmoglein-3 precursor
IPI:IPI00027462.1 6 13.2 6.13 0.297 0.224 Protein S100-A9
IPI:IPI00746049.1 3 131.1 6.20 0.326 0.212 Similar to Breast cancer antigen NY-BR-1.1
IPI:IPI00007047.1 2 10.8 7.03 0.351 0.186 Protein S100-A8
IPI:IPI00619932.4 2 265.2 8.53 0.382 0.047 CREB-binding protein
IPI:IPI00027412.4 2 37.2 5.82 0.470 0.086 Carcinoembryonic antigen-related cell adhesion
molecule 6
IPI:IPI00168698.1 2 128.5 6.09 0.470 0.136 PDZ domain-containing protein 8
IPI:IPI00657779.1 2 16.5 9.58 0.492 0.172 Peptidylprolyl isomerase F
IPI:IPI00646867.1 4 49.6 5.25 0.555 0.142 Vimentin
IPI:IPI00168913.1 2 139.8 6.65 0.738 0.269 Limbin, positive regulator of the hedgehog
signaling pathway
IPI:IPI00179700.3 3 11.7 10.32 1.227 0.179 High mobility group protein HMG-I/HMG-Y
IPI:IPI00021812.1 2 312.3 6.73 1.234 0.320 Neuroblast differentiation-associated protein AHNAK
IPI:IPI00183085.2 2 35.2 6.34 1.282 0.112 Highly similar to N-myc downstream regulated 1
IPI:IPI00410096.1 3 197.5 6.13 1.333 0.267 Selective LIM binding factor homolog
IPI:IPI00414203.2 3 81.4 5.97 1.351 0.265 Predicted testis protein
IPI:IPI00220709.3 9 33.0 4.67 1.386 0.160 Isoform 2 of Tropomyosin beta chain
IPI:IPI00220827.4 3 4.9 5.36 1.392 0.108 Thymosin beta-10
IPI:IPI00009771.5 2 69.9 5.59 1.440 0.451 Lamin-B2
IPI:IPI00375141.1 5 412.1 5.83 1.456 0.421 Dystrophin, morphogenesis and DNA-dependent
regulation of transcription
IPI:IPI00005750.1 3 255.3 9.11 1.840 0.499 Polycystic kidney disease and receptor for egg
jelly-related protein
CSC, cancer stem cells; MW, molecular weight.
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Figure 5 Western blot analysis of CREB-1, phospho-CREB1 (p-CREB-1) and CREB-binding protein (CBP) between CSC-like and non-CSC
UM1 cells (A). The normalized level of p-CREB-1 or CBP against β-actin is shown in (B) and (C). Both CBP and p-CREB-1 were significantly
(P <0.0005, n = 3) over-expressed in CSC-like UM1 cells when compared to non-CSC UM1 cells. CSC, cancer stem cells.
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units) was found to be over-expressed in CSC-like cells
compared to non-CSC UM1 cells. ATP synthase is an im-
portant enzyme that provides cells with energy through
the synthesis of ATP. Down-regulation of ATP synthase
β-subunit expression was reported in liver, kidney, colon,
squamous esophageal and lung carcinomas, as well as in
breast and gastric adenocarcinomas, indicating that bio-
energetic dysfunction of mitochondria is a hallmark of
these types of cancers [38-40]. However, in our present
study, mitochondrial ATP synthase was up-regulated in
CSC-like UM1 cells, suggesting an increase of mitochon-
drial bioenergetic production in CSC-like cells when com-
pared to non-CSC cells. This is in agreement with the
observation of a compromised glycolysis as indicated by
down-regulation of HIF-1α and glycolytic enzyme PGK1
(Figure 2). Together these results seem to suggest that
there is a shift from glycolytic to mitochondrial bio-
energetic production in CSC-like cells when compared to
non-CSC cells.
Our study also indicates that a group of small G
proteins were over-expressed in CSC-like cells versus
non-CSC cells (Table 3). Previous studies, indeed, have
revealed important roles for G proteins and G protein-
coupled receptors in regulating stem cell function. For
instance, signaling mediated by G proteins has been
shown to regulate pluripotency/differentiation in mouse
embryonic stem cells or human hematopoietic stem cells
and affect the morphology and organization of inducible
pluripotent stem cell colonies [41-43]. In addition, many
of the pathways downstream of G protein signaling di-
rectly regulate, or are synergistic with, the pathways that
are critical in regulating stem cell pluripotency anddifferentiation, such as SMAD/Nanog signaling, PI3K/
AKT, MAP kinase/cJun/cFos as well as GSK3/β-catenin
[44]. Thus, it is not surprising that small G proteins are
implicated as regulators of pluripotency and differentia-
tion in diverse stem cell populations.
Lastly, a number of differentially expressed proteins
identified by proteomic analysis may have functions re-
lated to development or differentiation (Table 4). For
instance, we found that the expression of carcinoem-
bryonic antigen-related cell adhesion molecule 6 (CEA-
CAM6) was elevated in CSC-like UM1 cells. Previous
studies indeed demonstrated that CEACAM6 is a novel
marker for colorectal cancer stem cells [45] and may
serve as a potential therapeutic target for pancreatic
adenocarcinoma [46]. Significant over-expression (seven-
fold) of desmoglein 3 (DSG3) was also observed in CSC-
like UM1 cells. The functional role and clinical utility of
DGS3 in head and neck cancer have been studied previ-
ously. Chen et al. found that the expression levels of
DSG3 were correlated with clinicopathologic features of
head and neck tumors and DSG3-positive cancer cells
represented a more aggressive cancer phenotype [47].
Ferris et al. discovered that DSG3 (also known as, pem-
phigus vulgaris antigen) is a highly valuable biomarker
for detection of lymph node metastasis in head and neck
cancer. Combining sentinel node biopsy with qPCR tes-
ting of DSG3/PVA may allow intraoperative staging of
HNSCC for treatment decision-making [48-50]. In
addition, we found that vimentin, which is a strong
indicator of epithelial-mesenchymal transition (EMT),
was up-regulated in spherogenic UM1 cells versus non-
spherogenic cells (non-CSC:CSC-like = 0.555, Table 4).
This is in line with previous studies which demonstrated
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cancer cells. The activation of EMT programs has been
associated with the acquisition of stem cell traits by nor-
mal and neoplastic cells. The connection between EMT
and stem cells seems to indicate that epithelial stem cells
express a wide array of mesenchymal markers and EMT
programs would seem to provide a ready source of CSCs
by enabling the dedifferentiation of the more epithelial
cells within carcinomas [51-53].
Our study revealed that the CREB pathway is activated
in CSC-like UM1 cells. CREB-1 can be activated by var-
ious cellular kinases including ribosomal protein S6 ki-
nase pp90RSK [54], protein kinase C [55], AKT/protein
kinase B [56], mitogen- and stress-activated protein
kinase (MSK-1) [57], MAPKAP-2 [58], and calcium/
calmodulin kinases [59], subsequently activating CREB
in cells. The crucial event in the activation of CREB
is the phosphorylation of Ser133 in KID (kinase-indu-
cible domain), which triggers the recruitment of tran-
scriptional co-activators such as CBP and p300 [18].
In the present study, we found that CBP was over-
expressed and CREB-1 was highly phosphorylated in
spherogenic UM1 cells, suggesting that the CREB pathway
is activated in these CSC-like cells. Since the cells were
cultured in serum-free medium containing bFGF and
EGF, very likely these growth factors up-regulated the
expression of kinases such as MSK-1 [18] in a small
subset of UM1 cancer cells (CSC-like cancer cells) and
subsequently activated CREB-1. However, why EGF and
bFGF activate the CREB pathway only in a specific sub-
set of CSC-like UM1 cells but not the other non-CSC
cancer cells remains to be further elucidated.
Conclusions
As a summary, we have found that the highly invasive
UM1 oral cancer cell line harbors a subset of CSC-like
cancer cells whereas the low invasive UM2 oral cancer
cell line does not. By using serum-free medium contain-
ing the growth factors bFGF and EGF for cell culture,
we were able to enrich and harvest CSC-like UM1 can-
cer cells. Stem cell markers such as SOX2, OCT4, SOX9
and CD44 were found to be up-regulated whereas HIF-
1α and PGK1 were down-regulated in the CSC-like cells
compared to non-CSC cells. Comparative proteomic ana-
lysis revealed that many proteins on cell cycle, meta-
bolism, small G protein signal transduction, translational
elongation, development, and RNA splicing pathways are
differentially expressed between the two cell phenotypes.
In particular, we found CBP was over-expressed and
CREB-1 was heavily phosphorylated in CSC-like cells.
This suggests that the CREB pathway is activated and
may play an important role in maintaining the stem-
ness in the CSC-like cancer cells. There have been
few studies on the role of the CREB pathway in stemcell function. Cheng et al. found that CREB is highly
expressed in lineage negative hematopoietic stem cells
and serves as a critical regulator of normal hematopoiesis
and leukemogenesis [60]. To the best of our knowledge,
this is the first study reporting a potential role of CREB-1
in solid tumor stem-like cells. However, the main weak-
ness of the current study is that we have not demonstrated
that the enriched CSC-like UM1 cells are capable of initi-
ating in vivo tumors. In the future, we will use a xeno-
grafted transplantation assay to study if spherogenic UM1
cells enhance tumorigenicity in vivo when compared to
non-CSC or parental UM1 cells. We will also investigate if
CREB-1 is required for regulating the self- renewal and/or
differentiation of oral/head and neck CSC-like cells and
how the CREB pathway is activated in the oral CSC-like
cells. These studies will confirm that the spherogenic
UM1 cells are indeed CSCs and may demonstrate poten-
tial targets of therapeutic intervention in oral cancer.
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